CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo

Huntington disease (HD) is a fatal dominantly inherited neurodegenerative disorder caused by CAG repeat expansion (>36 repeats) within the first exon of the huntingtin gene. Although mutant huntingtin (mHTT) is ubiquitously expressed, the brain shows robust and early degeneration. Current RNA interference-based approaches for lowering mHTT expression have been efficacious in mouse models, but basal mutant protein levels are still detected. To fully mitigate expression from the mutant allele, we hypothesize that allele-specific genome editing can occur via prevalent promoter-resident SNPs in heterozygosity with the mutant allele. Here, we identified SNPs that either cause or destroy PAM motifs critical for CRISPR-selective editing of one allele versus the other in cells from HD patients and in a transgenic HD model harboring the human allele.

[1]  G. Bonvento,et al.  Sustained effects of nonallele‐specific Huntingtin silencing , 2009, Annals of neurology.

[2]  Jennifer Doudna,et al.  RNA-programmed genome editing in human cells , 2013, eLife.

[3]  Elena Cattaneo,et al.  Molecular mechanisms and potential therapeutical targets in Huntington's disease. , 2010, Physiological reviews.

[4]  Jin-Soo Kim,et al.  Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases , 2014, Bioinform..

[5]  B. Davidson,et al.  Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  D. Rubinsztein,et al.  Functional analysis of the Huntington's disease (HD) gene promoter. , 1998, Human molecular genetics.

[7]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[8]  Feng Zhang,et al.  Genome engineering using CRISPR-Cas9 system. , 2015, Methods in molecular biology.

[9]  Martin J. Aryee,et al.  GUIDE-Seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases , 2014, Nature Biotechnology.

[10]  J. Botas,et al.  Huntingtin proteolysis releases non‐polyQ fragments that cause toxicity through dynamin 1 dysregulation , 2015, The EMBO journal.

[11]  J. Keith Joung,et al.  Improving CRISPR-Cas nuclease specificity using truncated guide RNAs , 2014, Nature Biotechnology.

[12]  Israel Steinfeld,et al.  Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells , 2015, Nature Biotechnology.

[13]  M. Isalan,et al.  Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice , 2012, Proceedings of the National Academy of Sciences.

[14]  D. Housman,et al.  Potential function for the Huntingtin protein as a scaffold for selective autophagy , 2014, Proceedings of the National Academy of Sciences.

[15]  Seung Woo Cho,et al.  Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease , 2013, Nature Biotechnology.

[16]  Feng Gu,et al.  Comparison of non-canonical PAMs for CRISPR/Cas9-mediated DNA cleavage in human cells , 2014, Scientific Reports.

[17]  Shihua Li,et al.  Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis , 2016, Proceedings of the National Academy of Sciences.

[18]  René Hen,et al.  Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease , 2000, Cell.

[19]  J. Doudna,et al.  A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.

[20]  David A. Scott,et al.  Double Nicking by RNA-Guided CRISPR Cas9 for Enhanced Genome Editing Specificity , 2013, Cell.

[21]  J. Lucas,et al.  Full Motor Recovery Despite Striatal Neuron Loss and Formation of Irreversible Amyloid-Like Inclusions in a Conditional Mouse Model of Huntington's Disease , 2005, The Journal of Neuroscience.

[22]  James E. DiCarlo,et al.  RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.

[23]  A. Regev,et al.  Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System , 2015, Cell.

[24]  M. Jinek,et al.  Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease , 2014, Nature.

[25]  L. Shihabuddin,et al.  Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis , 2012, Neuron.

[26]  Tammy Gillis,et al.  Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR/Cas9. , 2016, Human molecular genetics.

[27]  C. Bennett,et al.  Synthetic CRISPR RNA-Cas9–guided genome editing in human cells , 2015, Proceedings of the National Academy of Sciences.

[28]  H. Paulson,et al.  RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  D. Lowenstein,et al.  Mild experimental brain injury in the rat induces cognitive deficits associated with regional neuronal loss in the hippocampus. , 1993, Journal of neurotrauma.

[30]  J. Cummings,et al.  Huntington's disease. , 1997, The Psychiatric clinics of North America.

[31]  Carlos Cepeda,et al.  Full-Length Human Mutant Huntingtin with a Stable Polyglutamine Repeat Can Elicit Progressive and Selective Neuropathogenesis in BACHD Mice , 2008, The Journal of Neuroscience.

[32]  Mazhar Adli,et al.  Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease , 2014, Nature Biotechnology.

[33]  I. Martins,et al.  Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  David A. Scott,et al.  In vivo genome editing using Staphylococcus aureus Cas9 , 2015, Nature.

[35]  J. Keith Joung,et al.  High frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells , 2013, Nature Biotechnology.

[36]  Charles E. Vejnar,et al.  CRISPRscan: designing highly efficient sgRNAs for CRISPR/Cas9 targeting in vivo , 2015, Nature Methods.

[37]  M. White,et al.  Exploiting the CRISPR/Cas9 PAM Constraint for Single-Nucleotide Resolution Interventions , 2016, PloS one.

[38]  J. Joung,et al.  High-fidelity CRISPR-Cas9 variants with undetectable genome-wide off-targets , 2015, Nature.

[39]  David A. Scott,et al.  Rationally engineered Cas9 nucleases with improved specificity , 2015, Science.

[40]  Eli J. Fine,et al.  DNA targeting specificity of RNA-guided Cas9 nucleases , 2013, Nature Biotechnology.

[41]  M. Nesbit,et al.  CRISPR/Cas9 DNA cleavage at SNP-derived PAM enables both in vitro and in vivo KRT12 mutation-specific targeting , 2015, Gene Therapy.

[42]  Jennifer A. Doudna,et al.  DNA interrogation by the CRISPR RNA-guided endonuclease Cas9 , 2014, Nature.

[43]  J. Keith Joung,et al.  731. High-Fidelity CRISPR-Cas9 Nucleases with No Detectable Genome-Wide Off-Target Effects , 2016 .

[44]  B. Davidson,et al.  Huntington's disease: progress toward effective disease-modifying treatments and a cure. , 2010, Human molecular genetics.